Labels for the Pfizer and Moderna shots, which already caution about myocarditis and pericarditis, will more strongly stress ...

The procedures are not mutually exclusive, however, and should be considered on a patient-by-patient basis, a researcher says ...

This month: pharmacy’s growing CICU role, arrhythmias’ impact on pregnancy, Life’s Essential 8 in practice, and more.

PanEcho isn’t yet ready to be a standalone tool, researchers say, but shows promise at improving workflows and patient care.

Combination therapy with a long-acting amylin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist results in ...

In an early look at SCOT-HEART 2, CCTA led more primary-prevention patients to make changes to reduce their risk of CVD.

Acute MI mortality has fallen, yet deaths from other diseases, including heart failure and hypertension, are on the rise.

Cardiologists need to embrace the wave of new drugs, say experts, particularly since they can reduce the risk of CVD.

The once-monthly drug is still under study but could provide added convenience and another option for patients.

In DETECT AS, the passive notifications improved rates of AVR and boosted survival, with bigger gains in women.

The observational data can’t capture details like the timing, amount, and type of exposure. Still, there’s a “safety signal.” ...

Elevations in cardiac troponin (cTn) after long bouts of aerobic exercise are not associated with subclinical coronary artery ...